10-Q: Sono-Tek Reports Strong Q3 Profit Growth Amidst Shifting Markets

Sono-Tek Corporation announced a 24% increase in net income for the third quarter of fiscal 2026, driven by improved gross profit margins and operating leverage, despite a slight dip in overall sales.

Summary

• Net income for Q3 fiscal 2026 increased 24% to $339,959, and for the first nine months, it rose 32% to $1,248,637.
• Gross profit percentage improved to 50% in Q3 (from 45%) and 51% for the nine months (from 48%), attributed to a favorable product mix of high-ASP systems, reduced manufacturing costs, and strong U.S. sales with less discounting.
• Operating income surged 61% in Q3 to $318,972 and 69% for the nine months to $1,223,494, reflecting enhanced gross profit and operating leverage.
• Total net sales for Q3 fiscal 2026 were $5,004,370, a 3.6% decrease year-over-year, while nine-month sales were essentially flat at $15,299,839 (down 0.5%).
• Backlog reached a record $12.26 million at November 30, 2025, up 16% year-over-year and 9% sequentially.
• Medical sales increased 37% for the nine months, driven by strong demand for balloon catheter and stent coating systems.
• In-Line Coating Systems sales soared 126% for the nine months, including $5.9 million from eight high-ASP systems shipped to a major solar customer.
• Multi-Axis Coating Systems sales declined 46% for the nine months due to slower electrolysis demand following shifts in government policy incentives.
• Cash and cash equivalents, along with marketable securities, totaled $11.719 million at November 30, 2025, with no outstanding debt.
• Operating cash flow significantly decreased to $109,661 for the nine months, primarily due to a $2,063,899 increase in accounts receivable from revised payment terms for a large customer order.

Sentiment

Score: 7

Explanation: Despite a slight dip in overall sales, the company demonstrated strong profitability growth, significant margin expansion, and a record backlog. The strategic shift to higher-value systems is paying off. However, the substantial decrease in operating cash flow due to increased accounts receivable and high customer concentration are areas of concern that temper the overall positive sentiment.

Positives

• Significant increase in net income: 24% for Q3 ($339,959) and 32% for nine months ($1,248,637).
• Improved gross profit margins: 50% in Q3 (up 500 bps) and 51% for nine months (up 300 bps), driven by favorable product mix and reduced costs.
• Strong operating income growth: 61% in Q3 ($318,972) and 69% for nine months ($1,223,494).
• Record equipment and service-related backlog of $12.26 million, up 16% year-over-year and 9% sequentially.
• Robust growth in Medical sales (up 37% for nine months) and In-Line Coating Systems sales (up 126% for nine months, including $5.9 million from a major solar customer).
• No outstanding debt and a healthy cash and marketable securities balance of $11.719 million.
• Positive impact from the One Big Beautiful Bill Act (OBBBA) on income taxes, including 100% bonus depreciation and immediate expensing of R&D costs, potentially generating tax refunds.
• Seventh consecutive quarter with revenue exceeding $5 million.

Negatives

• Overall net sales decreased 3.6% in Q3 to $5,004,370 and were essentially flat (down 0.5%) for the nine months.
• Multi-Axis Coating Systems sales declined significantly by 53% in Q3 and 46% for the nine months, primarily due to reduced demand for electrolysis-related applications following shifts in U.S. government policy incentives.
• Alternative energy market sales declined 35% in Q3, also due to shifting government policy incentives.
• Net cash provided by operating activities decreased substantially to $109,661 for the nine months, down from $1,199,318 in the prior year, largely due to a significant increase in accounts receivable.
• Accounts receivable increased by $2,063,899 for the nine months, partly due to a customer requesting a two-month delay in a scheduled payment for a $5.9 million order.
• Foreign sales decreased in both the third quarter (32% of total sales vs 46% prior year) and the nine-month period (37% vs 39% prior year).
• Latin America sales declined 50% in Q3 and 48% for the nine months.
• One customer accounted for 67% of outstanding accounts receivables at November 30, 2025, indicating high customer concentration risk.

Risks

• General economic and business conditions, including inflationary and supply chain pressures.
• Political, regulatory, and tax developments affecting operations or product demand.
• Dependence on the recovery of the Electronics/Microelectronics and Medical markets.
• Risk of continued depletion of excess inventory by OEM Partners.
• Impact of tariffs.
• Timely development and market acceptance of new products.
• Adequacy of financing.
• Ability to enforce patents.
• Maintenance of operating leverage.
• Consummation of order proposals and completion of large orders on schedule and on budget.
• Fluctuations in order flow and shipments from quarter to quarter.
• High customer concentration, with one customer accounting for 67% of outstanding accounts receivables at November 30, 2025.
• Exposure to changes in U.S. government policy incentives, which negatively impacted alternative energy sales (electrolysis-related demand).
• Bank deposits exceeding FDIC insured limits ($2,718,000 at November 30, 2025).

Future Outlook

The company anticipates a rebound of sales to the industrial market in the fourth quarter of fiscal year 2026 and expects continued depletion of excess inventory by OEM Partners. It also foresees continued positive impact from recent distributor changes on Printed Circuit Board revenues and the maintenance of increased order backlog. The company aims for continued sales growth in the medical and alternative energy markets and a successful transition to providing complete machine solutions and higher value subsystems.

Management Comments

• Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability.
• Over the last decade, we have shifted our business from primarily selling ultrasonic nozzles and components to providing complete machine solutions and higher-value subsystems to original equipment manufacturers (OEMs).
• This strategy has resulted in significant growth of our average unit selling price, with our larger machines often selling for over $300,000 and system prices sometimes reaching over $1,000,000.
• We expect that we will experience wide variations in both order flow and shipments from quarter to quarter.
• Medical-related order activity and backlog continued to strengthen during the period.
• Based on our long-standing relationship and ongoing communications, we do not currently foresee any collection issues with this customer [with delayed payment].

Industry Context

Sono-Tek operates in a specialized niche within advanced manufacturing, providing ultrasonic coating systems critical for high-tech industries. The shift towards higher-value, complete machine solutions aligns with a broader industry trend of offering integrated systems rather than just components, allowing for increased average selling prices and market expansion. The company's strong performance in medical and solar (alternative energy, specifically In-Line Coating Systems) reflects growing demand in these sectors for precision coating technologies. However, the decline in Multi-Axis Coating Systems due to shifting U.S. government policy incentives for electrolysis-related applications highlights the sensitivity of certain segments to regulatory changes, a common factor in the rapidly evolving clean energy sector. The increase in fluxing systems demand in Asia (outside China) for PCB manufacturing indicates regional market strength in electronics.

Comparison to Industry Standards

• The company's transition from selling components to complete machine solutions with average selling prices exceeding $300,000 and sometimes $1,000,000 suggests a move up the value chain, which is a positive strategic development often seen in mature, specialized technology sectors.
• The reported gross profit margins of 50-51% are generally healthy for a manufacturing company, especially one involved in high-tech, custom-engineered solutions.
• The record backlog of $12.26 million indicates strong future demand, which is a positive indicator compared to industry peers facing uncertain order flows.
• The significant customer concentration (one customer accounting for 67% of receivables) is a notable point that would typically be higher than industry best practices for risk diversification.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, improved margins, and record backlog, potentially leading to increased shareholder value. However, decreased operating cash flow and customer concentration could be a concern.
• Employees: Continued investment in R&D and sales application labs suggests stable to growing employment opportunities, though some departures were noted in R&D and sales. Stock-based compensation plans provide incentives.
• Customers: Benefit from the company's focus on custom-engineered solutions, expanding testing labs, and transition to higher-value machine solutions. One major customer experienced a payment delay, which was accommodated.
• Suppliers: No specific impact mentioned, but inventory reduction suggests efficient supply chain management.
• Creditors: Strong liquidity with no outstanding debt on credit lines indicates low credit risk.

Next Steps

• Continue to expand sales capabilities by increasing direct sales force and adding new distributors and sales representatives.
• Further develop custom solutions for customers through expanded testing labs globally.
• Focus on leveraging innovative technologies, proprietary know-how, and global reach to develop thin-film coating technologies.
• Monitor the recovery of the Electronics/Microelectronics and Medical markets.
• Observe the rebound of sales to the industrial market in the fourth quarter of fiscal year 2026.
• Track the continued depletion of excess inventory by OEM Partners.
• Assess the continued positive impact of recent distributor changes on Printed Circuit Board revenues.
• Maintain increased order backlog.
• Continue sales growth in the medical and alternative energy markets.
• Successfully transition from primarily selling ultrasonic nozzles and components to complete machine solutions and higher value subsystems.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05) on consolidated financial statements and disclosures.

Key Dates

Recommendation

While Sono-Tek demonstrates strong profitability growth, margin expansion, and a record backlog, the flat sales growth and significant decline in operating cash flow due to a large increase in accounts receivable from a concentrated customer base present notable concerns. The strategic shift to higher-value systems is positive, but the impact of government policy changes on key markets like alternative energy introduces volatility. Given the mixed signals of strong underlying profitability and strategic progress against operational and market-specific headwinds, a 'hold' recommendation is appropriate for investors to monitor the resolution of the accounts receivable issue and the consistency of sales growth in key segments.

Keywords

ultrasonic coating systems, microelectronics, alternative energy, medical devices, industrial manufacturing, R&D, thin film coatings, OEM, fluxing systems, in-line coating systems, multi-axis coating systems, SEC filing, 10-Q, financial results, gross profit, net income, backlog, operating income, cash flow, accounts receivable, tax incentives, bonus depreciation, R&D expensing